Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge


The current study investigated the immunogenicity and protective response of rPA antigen formulated with the DPXTM no-release delivery platform (DPX-rPA). This unique formulation promotes a depot effect that attracts antigen-presenting cells to the vaccination site and elicits an immune response following single-dose delivery.

Content Information

Content Author: 
Genevieve M. Weir, Lisa D. MacDonald, Rajkannan Rajagopalan

Content Source: 
npj Vaccines

Content Type: 
News